CardioVascular Resource Group is an inspired team of senior consultants committed exclusively to the study of cardiovascular drug markets and producing the most accurate, forward-looking, and detailed market planning resources available anywhere and supporting clients with valuable expert insight.
|
|
Our highly acclaimed publication series and consulting services provide comprehensive resources to the cardiovascular drug industry with practical guidance for advancing new product and brand initiatives, developing successful corporate and franchise strategies, and strengthening licensing and acquisition positions... more 
|
| |
|
Disease Area Reports
drill down deeply into key cardiovascular drug markets through expert primary research and rigorous secondary analysis to deliver comprehensive resources with extensive detail and cutting-edge insights.
Each report provides incisive assessments of epidemiology, diagnosis, current treatment, emerging trends, new drug developments, unmet needs, target product profiles, and market forecast…
more
|
|
|
Arrhythmias, 2010-2019
Atrial Fibrillation & Atrial Flutter6/4/2010 |
Chronic CAD, 2010-2019
Post-MI & Stable Angina6/4/2010 |
Type 2 Diabetes, 2010-2019
Type II Diabetes6/4/2010 |
Dyslipidemia, 2010-2019
Dyslipidemia6/4/2010 |
Heart Failure, 2010-2019
Acute & Chronic HF6/4/2010 |
|
Therapy Area Reports span across multiple cardiovascular diseases and their corresponding drug classes for a more strategic and expansive assessment of new drug opportunities in complex interrelated disease areas.
Each report provides unparalleled commercial insights from a fresh vantage point through a comprehensive assessment of drug classes and unique cross-analysis of their market potential in core and related disease areas...more
|
|
|
|
|
|
|
|
Your message was received. Thank you for contacting us with your request.
